Evidence map›Paper›PMID 37314691›Full record

ArticleJournal of racial and ethnic health disparities2024

Increasing Clinical Trial Participation of Black Women Diagnosed with Breast Cancer.

Ricki Fairley, James W Lillard, Alexandra Berk, Sophia Cornew, Joseph Gaspero, James Gillespie, LaTrisha L Horne, Sabrina Kidane, Sandra B Munro, Matthew Parsons and 5 more

Abstract read
In one paragraph

Article in Journal of racial and ethnic health disparities, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Improving treatment education in Black and South Asian women.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ricki FairleyTOUCH, The Black Breast Cancer Alliance, Annapolis, MD, USA.
James W LillardDepartment of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Alexandra BerkMedical Affairs, Invitae, San Francisco, CA, USA.
Sophia CornewPatient Network and Data, Invitae, San Francisco, CA, USA.
Joseph GasperoCenter for Healthcare Innovation, Chicago, IL, USA.
James GillespieCenter for Healthcare Innovation, Chicago, IL, USA.
LaTrisha L HorneDepartment of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Sabrina KidaneLRW A Material Company, Los Angeles, CA, USA.
Sandra B MunroMedical Affairs, Invitae, San Francisco, CA, USA.
Matthew ParsonsLRW A Material Company, Los Angeles, CA, USA.
Emily R PowersTOUCH, The Black Breast Cancer Alliance, Annapolis, MD, USA. emily@touchbbca.org.ORCID 0009-0009-9868-2516
Suzanne E RizzoBreastcancer.org, Ardmore, PA, USA.
Alyson TishclerLRW A Material Company, Los Angeles, CA, USA.
Hope WohlBreastcancer.org, Ardmore, PA, USA.
Marisa C WeissBreastcancer.org, Ardmore, PA, USA.

Funding

Eisai Incorporated $20,000Genentech $566,000
6 · The paper itself

Abstract

Despite racial disparities in breast cancer mortality, Black women remain underrepresented in clinical trials. In this mixed methods research, 48 Black women were engaged via focus group discussions and in-depth interviews to better understand the lived experience of women with breast cancer. The results of this qualitative study informed the development of a subsequent online survey to identify barriers, motivators, and other factors that influence decision-making by Black women diagnosed with breast cancer when considering clinical trial participation. Among the 257 Black survey participants, most (95%) were aware of clinical trials; of those, most viewed them as lifesaving (81%) and/or benefiting others (90%). Negative perceptions such as serious side effects (58%), not receiving real treatment (52%), or risk of potential harm (62%) were indicated. Barriers included financial expenses (49%), concerns that their condition could be made worse (29%), that they would receive a placebo (28%), or that treatment was unapproved (28%). Participants were more likely than their health care providers (HCPs) to initiate discussions of clinical trials (53% versus 33%), and 29% of participants indicated a need for more information about risks and benefits, even after having those conversations. The most trustworthy sources of information on clinical trials were HCPs (66%) and breast cancer support groups (64%). These results suggest that trusted communities are key for providing education on clinical trials. However, there is also a need for HCPs to proactively discuss clinical trials with patients to ensure that they are adequately informed about all aspects of participation.

Indexed as

Black or African AmericanBreast NeoplasmsClinical Trials as TopicQualitative ResearchAdultAgedDecision MakingFemaleFocus GroupsHealth Knowledge, Attitudes, PracticeHumansMiddle AgedPatient ParticipationBlack/African American WomenBreast CancerClinical TrialsHealth Disparities

Identifiers

PMID37314691
PMCPMC11101578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.